Minerva Neurosciences (NERV) logo

Minerva Neurosciences (NERV) stock

Worth $124MShares as of Nov 3

$2.49
-5.32%

As of Tuesday's close · Live for Pro members at the open

Not scored

Breakaway doesn't score NERV. It is too thinly traded for a fair Quality Score.

Healthcare · Pharma

Next2H 2027“We remain focused on execution and on track for topline efficacy data in the second half of 2027.”Trial data · SEC filing · Nov 6
Cash$76.9M, about 9 quarters (2.5 years) at the last year's spendingOn Sep 30

Follow NERV's trial news. Pro members can get an alert when Minerva Neurosciences files news, and see its trials, share raises, and its CEO's filings.

Get an alert when NERV files news on its trialSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. 3,168 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.

Cash$76.9M, about 9 quarters (2.5 years) at the last year's spendingOn Sep 30

What's next for NERV, and how long its cash lasts

Next step the company has named

2H 2027“We remain focused on execution and on track for topline efficacy data in the second half of 2027.”Trial data · SEC filing · Nov 6

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway
Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic MedicationsPhase 3 · Recruiting · 380 people · main data estimated Dec 2027 · NCT07565428

For Pro members: 1 more milestone and 21 filings.

Cash runway Sep 30 balance sheet

About 9 quarters

$76.9M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Mar 11, 2026)
  • At-the-market share sales program (424B5, filed May 27, 2026)

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Remy Luthringer’s 10 filings and quotes.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

NERV's latest filings

26 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why NERV isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares or $10M a day. NERV trades about 196,000 shares a day. A stock that clears every mark is scored from the next weekly rebuild.

Straight AnswersStraight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See every stock ranked

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

The price on this page is delayed at least 15 minutes.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.